ZOLGENSMA
STN: 125694
Proper Name: onasemnogene abeparvovec
Trade Name: ZOLGENSMA
Manufacturer: Novartis Gene Therapies, Inc.
Indication:
- Treatment of Spinal Muscular Atropy (Type I)
Product Information
Supporting Documents
- August 5, 2022 Approval Letter - ZOLGENSMA
- October 22, 2021 Approval Letter - ZOLGENSMA
- March 16, 2021 Approval Letter - ZOLGENSMA
- May 24, 2019 Approval Letter - ZOLGENSMA
- May 24, 2019 Summary Basis for Regulatory Action - ZOLGENSMA
- Approval History, Letters, Reviews, and Related Documents - ZOLGENSMA